# Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg

> **NCT00648063** · PHASE1 · COMPLETED · sponsor: **Mylan Pharmaceuticals Inc** · enrollment: 24 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Letrozole Tablets 2.5 mg
- **DRUG:** Femara® Tablets 2.5 mg

## Key facts

- **NCT ID:** NCT00648063
- **Lead sponsor:** Mylan Pharmaceuticals Inc
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11
- **Primary completion:** 2005-12
- **Final completion:** 2006-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2009-12-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00648063

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00648063, "Fasting Study of Letrozole Tablets 2.5 mg and Femara® Tablets 2.5 mg". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT00648063. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*